Collaboration designed to leverage Merus ’ Biclonics ® bispecific antibody technology to expand Incyte ’ s discovery capabilities and large-molecule portfolio Incyte to make up-front payment of $120 million and purchase $80 million of Merus common shares; Merus eligible to receive potential

European Patent Office Dismisses Arguments by Regeneron Favorable Rulings Further Strengthen IP Estate in Europe and Japan through 2029 UTRECHT, The Netherlands , Nov. 15, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific

UTRECHT, The Netherlands , Nov. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that Ton Logtenberg, CEO, will present at the Jefferies London Healthcare Conference on Thursday,

UTRECHT, The Netherlands and EDINBURGH, UK , Nov. 09, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that it has been awarded  a €1.5 million EUREKA Eurostars grant (“iMOD-ReACT”)

UTRECHT, The Netherlands , Nov. 07, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the third quarter ended September 30, 2016 and provided a review of recent

Former CFO Shelley Margetson Elevated to Chief Operating Officer UTRECHT, The Netherlands , Nov. 03, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the appointment of John Crowley as

UTRECHT, The Netherlands , Oct. 26, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the appointment of L. Andres Sirulnik , MD, PhD, to the position of Chief Medical Officer, where he

UTRECHT, The Netherlands , Oct. 19, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company received an undisclosed milestone payment from Ono Pharmaceutical Co., LTD.

UTRECHT, The Netherlands , Aug. 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will participate in the following upcoming investor conferences: Ton Logtenberg,

UTRECHT, The Netherlands , Aug. 10, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced that the Company will present at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday,

UTRECHT, The Netherlands , Aug. 08, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced financial results for the second quarter ended June 30, 2016 and provided a review of recent

Raises $53.3 Million in Successful Initial Public Offering Doses First Patient in Phase 1/2 Study of MCLA-117 in Patients with AML UTRECHT, The Netherlands, July 12, 2016 (GLOBE NEWSWIRE) -- Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics,

Bispecific Cancer Antibody Pipeline Optimized by GlymaxX® Manufacturing Technology BERLIN & UTRECHT, The Netherlands , June  01, 2016  (GLOBE NEWSWIRE) -- ProBioGen AG and Merus N.V. (Nasdaq:MRUS) today jointly announced that Merus has signed a commercial multi-product license

UTRECHT, the Netherlands, May 31, 2016 (GLOBE NEWSWIRE) -- Merus N.V. ("Merus") ( MRUS ), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the closing of a partial exercise of the over-allotment option by the underwriters of its

UTRECHT, the Netherlands , May 24, 2016 (GLOBE NEWSWIRE) -- Merus N.V. (“Merus”) (Nasdaq:MRUS) today announced the closing of its initial public offering of 5,500,000 common shares at an initial public offering price of $10.00 per share.  The shares began trading on The NASDAQ Global Market under

UTRECHT, the Netherlands , May 18, 2016 (GLOBE NEWSWIRE) -- Merus B.V. (“Merus”) today announced the pricing of its initial public offering of 5,500,000 common shares at an initial public offering price of $10.00 per share, before underwriting discounts and commissions.

UTRECHT, The Netherlands (GLOBE NEWSWIRE) — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the first patient has been dosed in the Company's Phase 1/2 clinic al trial evaluating MCLA-117 as a potential treatment of

MCLA-128 Shows Favorable Safety Profile and Early Signs of Anti-Tumor Activity in Patients with Advanced Solid Tumors UTRECHT, The Netherlands, April 15, 2016 (GLOBE NEWSWIRE) -- Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics),

Utrecht, The Netherlands, March 9, 2016 - Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, announced today that the United States Patent and Trademark Office (USPTO) has issued three patents related to the generation of bispecific

Utrecht, The Netherlands and Villejuif, France, January 4, 2016 — Merus B.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and Institut Gustave Roussy, a leading Comprehensive Cancer Centre in Europe, today announced entry into a strategic